Navigation Links
TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
Date:11/13/2011

MALVERN, Pa., Nov. 13, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors.

In a poster entitled "Phase 1 PK/PD Analysis of the Smac Mimetic TL32711 Demonstrates Potent and Sustained cIAP1 Suppression in Patient PBMC and Tumor Biopsies" (Abstract # A25), the degradation and suppression of cIAP1 was analyzed as part of the single agent Phase 1 study. The data demonstrated that TL32711 causes potent and sustained suppression of inhibitor of apoptosis protein cIAP1 in patient peripheral blood mononuclear cells (PBMCs) and tumor biopsies over 7 days at tolerable dose levels with evidence of apoptosis pathway activation and promising early signs of anti-tumor activity in patients.

In a poster entitled "Dose scheduling and efficacy analysis of the Smac mimetic TL32711 in primary melanoma tumor xenotransplant models" (Abstract # A225), tumor growth inhibition was observed in primary melanoma tumor xenografts following treatment with single agent TL32711.  Combining TL32711 with carboplatin and paclitaxel resulted in a further enhancement in anti-tumor efficacy with tumor regressions without any marked changes in tolerability.

About TL32711

TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors. In the clinical studies to date, TL32711 has been well tolerated and exhibited target suppression and antitumor activity.

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.

Media Contact:

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
tony.russo@russopartnersllc.com
andreas.marathis@russopartnersllc.com

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900


'/>"/>
SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
3. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
(Date:2/11/2016)... 2016  Governor Andrew M. Cuomo today announced a ... throughout Western New York . This ... Polytechnic Institute, includes a major expansion of Athenex,s North ... Buffalo , as well as the creation of ... Dunkirk . The combined projects are expected ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... “ HEALING MIND : Five Steps to Ultimate Healing, Four Rooms ... teaches readers how to become their own therapist. Providing a useful step-by-step process for ... offers an understanding of how to heal one’s inner child using four archetypes of ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... (DMPG) will use the action analytics leader’s population health solutions, MDinsight® and ... clinical support to the Atlanta-area healthcare system. Details of the contract were not ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Registered nurses, ... free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, ... in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... Florida ... Bay Lightning take on the St. Louis Blues at the Amalie Arena. The puck ... portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA veteran franchise owner ... it’s the buildings of Nashville that will benefit. , “I’ve enjoyed being a part ... Nashville, there was no question that I would bring my business with me,” Bogacki ...
Breaking Medicine News(10 mins):